Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Using standard and ultrasensitive techniques, we detected nonnucleoside reverse-transcriptase inhibitor-associated resistance mutations in 11 (20%) of 54 subjects who discontinued virologically suppressive nonnucleoside reverse-transcriptase inhibitor-containing antiretroviral therapy. Resistance was detected in 45% and 14% of subjects with a baseline human immunodeficiency virus type 1 RNA level of 51-400 copies/mL and <or=50 copies/mL, respectively. Mutations remained detectable for at least 48 weeks in some subjects.
Hare
C Bradley
CB
Dept of Medicine, University of California, San Francisco, CA 94110, USA. chare@php.ucsf.edu
Mellors
John
J
Krambrink
Amy
A
Su
Zhaohui
Z
Skiest
Daniel
D
Margolis
David M
DM
Patel
Sheran S
SS
Barnas
Douglas
D
Frenkel
Lisa
L
Coombs
Robert W
RW
Aweeka
Francesca
F
Morse
Gene D
GD
Haas
David W
DW
Boltz
Valerie
V
Palmer
Sarah
S
Coffin
John
J
Havlir
Diane V
DV
D000328:Adult; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*; D019562:Viral Load
D018894:Reverse Transcriptase Inhibitors